Loading
TRI-611 is an experimental protein degrader from TRIANA Biomedicines in phase 2 trials for non-small-cell lung cancer, aimed at ALK.
TRI-611 is a protein degrader developed by TRIANA Biomedicines. Its target is ALK (the sponsor names ALK). The sponsor states: TRI-611 is an oral, brain-penetrant molecular glue degrader that brings ALK fusion proteins and cereblon together through a mechanism independent of the kinase active site, driving degradation of ALK fusion proteins in ALK-positive NSCLC. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in non-small-cell lung cancer. The largest, NCT07491497, plans to enrol 160 participants with primary completion expected 2029-05-31. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
TRI-611 is an oral, brain-penetrant molecular glue degrader that brings ALK fusion proteins and cereblon together through a mechanism independent of the kinase active site, driving degradation of ALK fusion proteins in ALK-positive NSCLC. Connects to ALK.
1.TRI-611 binds ALK with one end and an E3 ubiquitin ligase with the other.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"TRI-611" OR ABSTRACT:"TRI-611") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TRI-611, not a curated reading list.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.